Know Cancer

forgot password

LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

18 Years
Not Enrolling
T-Cell Lymphoma

Thank you

Trial Information

LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and
refractory diseases that are generally treated with chemotherapy. Despite current treatment
modalities, only a subset of patients will be cured by the treatment. In this study, four
chemotherapeutic agents (L-asparaginase, Methotrexate, Doxil, and Prednisone) will be
administered in a combination regimen for patients with relapsed or refractory Peripheral
and/or advanced cutaneous T cell lymphoma. Each one of these individual drugs have been
shown to have activity to lymphomas. The objective of the study is to determine if the
combination of these chemotherapy agents results in higher response and cure rates in this
patient population. This will be a single institutional study which will included 32
patients in the Peripheral T cell lymphoma group and 32 patients in the Cutaneous T cell
lymphoma group.

Inclusion Criteria


Patients must be at least 18 years of age. Histologically confirmed (including
immunohistochemistry) diagnosis of T-Cell Lymphoma by skin biopsy or visceral/lymph node
biopsy or bone marrow aspirate/biopsy Life expectancy of more than 3 months.


Uncontrolled diabetes mellitus Active or serious infections uncontrolled with antibiotics
Concurrent treatment, radiation or investigational treatment. 5.2.6 Significant underlying
cardiac disease, including unstable angina, myocardial infarction less than 6 months
before starting study, congestive failure of any cause

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluation of specific chemotherapy intervention

Principal Investigator

Roger Strair, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Medicine and Dentistry New Jersey


United States: Institutional Review Board

Study ID:




Start Date:

February 2005

Completion Date:

October 2007

Related Keywords:

  • T-Cell Lymphoma
  • T-Cell Lymphomas
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous



Cancer Institute of New Jersey New Brunswick, New Jersey  08901